Viewing Study NCT05219318


Ignite Creation Date: 2025-12-25 @ 5:03 AM
Ignite Modification Date: 2025-12-26 @ 4:06 AM
Study NCT ID: NCT05219318
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-06-04
First Post: 2022-01-20
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors
Sponsor: University Hospital, Bordeaux
Organization:

Key Dates - Follows AllAPIJSON File Order

Start Date: 2023-01-23
Start Date Type: ACTUAL
Primary Completion Date: 2027-01
Primary Completion Date Type: ESTIMATED
Completion Date: 2027-01
Completion Date Type: ESTIMATED
First Submit Date: 2022-01-20
First Submit QC Date: None
Study First Post Date: 2022-02-02
Study First Post Date Type: ACTUAL
Results First Submit Date: None
Results First Submit QC Date: None
Results First Post Date: None
Results First Post Date Type: None
Results First Post QC Date: None
Results First Post QC Date Type: None
Disp First Submit Date: None
Disp First Submit QC Date: None
Disp First Post Date: None
Disp First Post Date Type: None
Last Update Submit Date: 2025-06-03
Last Update Post Date: 2025-06-04
Last Update Post Date Type: ACTUAL